PV Bulletin

IB template for cell therapy products

A new Investigator’s Brochure (IB) template for cell therapy products has been released by the Danish Medicines Agency.

Primary source: Danish Medicines Agency (Lægemiddelstyrelsen)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Availability of a new Investigator’s Brochure (IB) template specifically for cell therapy products.

Why it matters

This standardization ensures consistent documentation of risk assessments and safety data, enhancing oversight during clinical trials.

Action needed

Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection Readiness
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Template
Policy status
new
Publication date
2026-06-25
Policy change
The Danish Medicines Agency released a new Investigator’s Brochure (IB) template specifically tailored for cell therapy products to streamline clinical trial applications and ensure comprehensive safety data reporting.

Key changes

Standardization of the IB format for cell therapy trials in Denmark.

Affected workflows

Inspection Readiness

Responsible groups

Clinical OperationsPV OperationsRegulatory Affairs

PV impact

Ensures that risk assessments and safety data for cell therapies are consistently documented in the IB, facilitating better safety oversight during clinical trials.

View regulator source

Source document details

Exact policy details

IB Template Availability
Available
Applies to: For cell therapy products
An IB template for cell therapy products is now available · p. 1 · High · Source
Guidance Location
Special Product Areas under Regulation of innovative medicinal products
Applies to: Clinical trial applications
The documents can be found under 'Special Product Areas', within 'Regulation of innovative medicinal products' · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Jun 25, 2026

Full briefing

Practical implication

Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.

The Danish Medicines Agency introduced an IB template specifically for cell therapy products to standardize clinical trial applications and improve safety data reporting.

What changed: Availability of a new Investigator’s Brochure (IB) template specifically for cell therapy products.

Why it matters: This standardization ensures consistent documentation of risk assessments and safety data, enhancing oversight during clinical trials.

Practical implication: Utilize the IB template provided for cell therapy products in clinical trial applications, available under the 'Special Product Areas' section of the Danish Medicines Agency's website.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Urgent Withdrawal of Reusable da Vinci S and Si Instruments Due to Cable Degradation

Urgency: High

Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.

Signal ManagementRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Latest
Read impact briefarrow_forward